Quand suspecter une maladie auto-inflammatoire chez l’adulte?

Main Article Content

Stéphanie Ducharme-Bénard
Gilles Grateau
Sophie Georgin-Lavialle

Abstract

Résumé
Le domaine des maladies auto-inflammatoires (MAI) est en plein essor, avec la découverte de nouvelles maladies à chaque année. À ce jour, plus d’une trentaine de MAI sont recensées. Plusieurs d’entre elles débutent ou sont diagnostiquées à l’âge adulte. Il est important de les reconnaître pour mieux les traiter et ainsi prévenir les conséquences, parfois graves, reliées à l’inflammation chronique ou récidivante qu’elles génèrent.


ABSTRACT
The field of auto-inflammatory diseases (AIDs) is booming, with new diseases being discovered every year. To date, more than 30 AIDs have been identified. Many of them begin or are diagnosed in adulthood. It is important to recognize them in order to better treat them and thus prevent the sometimes serious consequences related to the chronic or recurrent inflammation they generate.

Abstract 241 | pdf Downloads 84 html Downloads 54

References

1. Ben-Chetrit E, Gattorno M, Gui A, et al. Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Ann Rheum Dis. 2018; 77(11): 1558-1565.
2. Ben-Chetrir E, Touitou I. Familial Mediterranean Fever in the World. Arthritis Rheum. 2009; 61(10): 1447-1453.
3. Zhang S. Natural history of mevalonate kinase deficiency: a literature review. Pediatr Rheumatol Online J. 2016; 14(1): 30.
4. Hausmann JS, Lomax KG, Shapiro A, et al. The patient journey to diagnosis and treatment of autoinflammatory diseases. Orphanet J Rare Dis. 2018; 13(1): 156.
5. Chuamanochan M, Weller K, Feist E, et al. State of care for patients with systemic autoinflammatory diseases - Results of a tertiary care survey. World Allergy Organ J. 2019; 12(3): 100019.
6. David K, Yougstein T, Lane T, et al. Retrospective Analysis of Adult Referrals to the Periodic Fever Service at the National Amyloidosis Centre: Increasing Recognition of Adult-Onset Genetic Autoinflammatory Disease. Rheumatology. 2016; 55(1): i47.
7. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 3.8 (2006): e297.
8. The French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 1997; 17: 25-31.
9. The international FMF Consortium. Ancient Missense Mutations in a New Member of the RoRet Gene Family Are Likely to Cause Familial Mediterranean Fever. Cell Press. 1997; 90: 797-807.
10. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998; 351(9103): 659-664.
11. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial mediterranean fever. Arthritis Rheum. 1997; 40(10): 1879-1885.
12. Barzilai A, Langevitz P, Goldberg I, et al. Erysipelas-like erythema of familial Mediterranean fever: clinicopathologic correlation. J Am Acad Dermatol. 2000; 42(5 Pt 1): 791-5.
13. Majeed HA, Al-Qudah AK, Qubain H, et al. The clinical patterns of myalgia in children with familial Mediterranean fever. Semin Arthritis Rheum. 2000; 30(2): 138.
14. Livneh A, Langevitz P, Zemer D, et al. The changing face of Familial Mediterranean Fever. Semin Arthritis Rheum. 1996; 26(3): 612-627.
15. Altunoğlu A, Erten S, Canoz MB, et al. Phenotype 2 Familial Mediterranean Fever: Evaluation of 22 Case Series and Review of the Literature on Phenotype 2 FMF. Ren Fail. 2013; 35(2): 226-30.
16. Georgin-Lavialle S, Stankovic K, Cez A, et al. Amylose AA secondaire à la fièvre méditerranéenne familiale : à propos de 38 cas. Rev Med Interne. 2016; 37(2): A119-A120.
17. Hoffman HM, Muelle JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001; 29(3): 301-5.
18. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002; 46(12): 3340-8.
19. Labrousse M, Kevorkian-Verguet C, Boursier G, et al. Mosaicism in autoinflammatory diseases: Cryopyrin-associated periodic syndromes (CAPS) and beyond. A systematic review. Crit Rev Clin Lab Sci. 2018; 55(6): 432-442.
20. Kuemmerle-Deschner J. CAPS — pathogenesis, presentation and treatment of an autoinflammatory disease. 2017; 37(4).
21. Quartier P, Rodrigues F, Gerogin-Lavialle S. Cryopyrinopathies. La Revue de Médecine Interne. 2018; 39(4): 287-296.
22. Koné-Paut I. Syndrome périodique lié à la cryopyrine : CAPS vu à l’âge adulte. Rev Med Interne. 2015; 36(4): 277-282.
23. Levy R, Gérard L, Kuemmerle-Deschner J, et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis. 2015; 74: 2043-2049.
24. Parker T, Keddie S, Kidd D, et al. Neurology of the cryopyrin-associated periodic fever syndrome. Eur J Neurol. 2016; 73: 1145-1151.
25. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999; 97(1): 133-144.
26. Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2013; 73(12): 2160-2167.
27. Lachmann HJ. Periodic fever syndromes. Best Pract Res Clin Rheumatol. 2017; 31(4): 596-609.
28. Houten SM, van Woerden CS, Wijburg FA, et al. Carrier frequency of the V377I (1129G>A) MVK mutation, associated with Hyper-IgD and periodic fever syndrome, in the Netherlands. Eur J Hum Genet. 2003; 11(2): 196-200.
29. Jeyaratnam J, Ter Haar NM, de Sain-van der Velden MG, et al. Diagnostic Value of Urinary Mevalonic Acid Excretion in Patients with a Clinical Suspicion of Mevalonate Kinase Deficiency (MKD). JIMD Rep. 2016; 27: 33–38.
30. Ammouri W, Cuisset L, Rouaghe S, et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatol. 2007 ; 46(10): 1597–1600.
31. Ter Haar NM, Jeyaratnam J, Lachmann HJ, Jeyaratnam J, et al. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis Rheumatol. 2016; 68(11): 2795–2805.
32. Van der Hilst JC, Bodar EJ, Barron KS, et al. Long-Term Follow-Up, Clinical Features, and Quality of Life in a Series of 103 Patients With Hyperimmunoglobulinemia D Syndrome. Medicine (Baltimore). 2008; 87(6): 301-310.
33. Durel CA, Aouba A, Bienvenu B, et al. Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency. Medicine (Baltimore). 2016; 95(11): e3027.
34. Wekell P, Karisson A, Berg S, et al. Review of autoinflammatory diseases, with a special focus on periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome. 2016; 105: 1140-1151.
35. Marshall GS, Edwards KM, Butler J, et al. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr. 1987; 110(1): 43-46.
36. Thomas KT, Feder HM Jr, Lawton AR, et al. Periodic fever syndrome in children. J Pediatr. 1999; 135: 15-21.
37. Vanoni F, Caorsi R, Aeby S, et al. Towards a new set of classification criteria for PFAPA syndrome. Pediatr Rheumatol Online J. 2018; 16(1): 60.
38. Harel L, Hashkes PJ, Lapidus S, et al.The First International Conference on Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis Syndrome. J Pediatr. 2018; 193: 265-274.e3.
39. Hofer M, Pillet P, Cochard MM, et al. International periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome cohort: description of distinct phenotypes in 301 patients. Rheumatology. 2014; 53(6): 1125-1129.
40. Wurster VM, Carlucci JG, Feder HM, et al. Long-term follow-up of children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome. J Pediatr. 2011; 159(6): 958-964.
41. Padeh S, Stoffman N, Berkun Y. Periodic fever accompanied by aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA syndrome) in adults. Isr Med Assoc J. 2008; 10: 358 –360.
42. Cantarini L, Vitale A, Bartolomei B, et al. Diagnosis of PFAPA syndrome applied to a cohort of 17 adults with unexplained recurrent fever. Clin Exp Rheumatol. 2012; 30(2): 269-271.
43. Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. NEJM. 2014; 370(10): 911-920.
44. Rama M, Duflos C, Melki I, et al. A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience. Eur J Hum Genet. 2018; 26: 960–971.
45. Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. NEJM. 2014; 370(10): 921–931.
46. Lee P. Vasculopathy, Immunodeficiency, and Bone Marrow Failure: The Intriguing Syndrome Caused by Deficiency of Adenosine Deaminase 2. Front Pediatr. 2018; 6: 282.
47. Meyts I, Aksentijevich I. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment. J Clin Immunol. 2018; 38(5): 569–578.
48. Ozen S, Bilginer Y, Batu ED, et al. A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase. J Rheumatol. 2019;: doi: 10.3899/jrheum.181384. [Epub ahead of print].
49. Zhou Q, Wang H, Schwartz DM, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2016; 48: 67–73.
50. Aeschlimann FA, Batu ED, Canna SW, et al. A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Ann Rheum Dis. 2018; 77(5): 728-735.
51. Kadowaki T, Ohnishi H, Kawamoto N, et al. Haploinsufficiency of A20 causes autoinflammatory and autoimmune disorders. J Allergy Clin Immunol. 2018; 141(4): 1485–1488.e11.
52. Berteau F, Rouviere B, Delluc A, et al Autosomic dominant familial Behçet disease and haploinsufficiency A20: A review of the literature. Autoimmun Rev. 2018; 17(8): 809-815.
53. Tsuchida N, Kirino Y, Soejima Y, et al. Haploinsufficiency of A20 caused by a novel nonsense variant or entire deletion of TNFAIP3 is clinically distinct from Behçet’s disease. Arthritis Res Ther. 2019; 21(1): 137.
54. Holzinger D, Fassl SK, de Jager W, et al. SdJWea. Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)–associated inflammatory diseases. J Allergy Clin Immunol. 2015; 136(5): 1337-1345.
55. Holzinger D, Roth J. Alarming consequences - autoinflammatory disease spectrum due to mutations in proline-serine-threonine phosphatase-interacting protein 1. Curr Opin Rheumatol. 2016; 28(5): 550-559.
56. Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc. 1997; 72(7): 611-615.
57. Sonbol H, Duchatelet S, Miskinyte S, et al. PASH syndrome (pyoderma gangrenosum, acne and hidradenitis suppurativa): a disease with genetic heterogeneity. Br J Dermatol. 2018; 178(1): e17-e18.
58. Masters SL, Lagou V, Jeru I, et al. Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation. Sci Transl Med. 2016; 8(332): 332ra45.
59. Moghaddas F, Llamas R, De Nardo D, et al. A novel Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis mutation further defines 14-3-3 binding of Pyrin and distinction to Familial Mediterranean Fever. Ann Rheum Dis. 2017; 76(12): 2085-2094.
60. Caso F, Galozzi P, Costa L, et al. Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open. 2015; 1(1): e000097.
61. Miceli-Richard C, Lesage S, Ryboiad M, et al. CARD15 mutations in Blau syndrome. Nat Genet. 2001; 29(1): 19-20.
62. Muscari I, Lacoponi F, Cantarini L, et al. The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: Our experience and review of the literature. Autoimmun Rev. 2012; 12(1): 10-13.
63. Cantarini L, Vitale A, Lucherini OM, et al. Childhood versus adulthood-onset autoinflammatory disorders: myths and truths intertwined. Rheumatismo. 2013; 65(2): 55-62.
64. Federici L, Rittore-Domingo C, Koné-Paut I, et al. A decision tree for genetic diagnosis of hereditary periodic fever in unselected patients. Ann Rheum Dis. 2006; 65(11): 1427-1432.
65. Sohar E, Gafni J, Pras M, et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967; 43(2): 227-253.
66. Üreten K, Gönülalan G, Akbal E, et al. Rheumatology International. 2010; 30(7): 911–915.
67. Kriegshauser G, Enko D, Hayrapetyan H, et al. Genotypic diversity observed within a large cohort of Armenian patients with late-onset familial Mediterranean fever. Genet Med. 2018; 20: 1583-1588.
68. Yasar Bilge NS, Sari I, Solmaz D, et al. Comparison of early versus late onset familial Mediterranean fever. Int J Rheum Dis, 21: 880-884. Int J Rheum Dis. 2018; 21: 880-884.
69. Tamir N, Langevitz P, Zemer D, et al. Late onset familial Mediterranean fever (FMF): a subset with distinct clinical, demographic, and molecular genetic characteristics. Am J Med Genet. 1999; 87: 30-35.
70. Sayarlioglu M, Cefle A, Inanc M, et al. Characteristics of patients with adult-onset familial Mediterranean fever in Turkey: analysis of 401 cases. Int J Clin Pract. 2005; 59(2): 202-205.
71. Nobakht H, Zamani F, Ajdarkosh H, et al. Adult-Onset Familial Mediterranean Fever in Northwestern Iran; Clinical Feature and Treatment Outcome. Middle East J Dig Dis. 2011; 3(1): 50-55.
72. Marek‐Yagel D, Berkun Y, Padeh S, et al. Clinical disease among patients heterozygous for familial mediterranean fever. Arthritis Rheumatol. 2009; 60(6): 1862-1866.
73. Hoffman HM, Broderick L. Editorial: It Just Takes One: Somatic Mosaicism in Autoinflammatory Disease. Arthritis Rheumatol. 2017; 69(2): 253-256.
74. Stoffels M, Kastner DL. Old Dogs, New Tricks: Monogenic Autoinflammatory Disease Unleashed. Annu Rev Genomics Hum Genet. 2016; 17(1): 245-272.
75. Forsberg LA, Gisselsson D, Dumanski JP. Mosaicism in health and disease – clones picking up speed. Nat Rev Genet. 2017; 18(2): 128–142.
76. De Inocencio J, Mensa-Vilaro A, Tejada-Palacios P, et al. Somatic NOD2 mosaicism in Blau syndrome. J Allergy Clin Immunol. 2015; 136(2): 484-487.e2.
77. Mensa-Vilaro A, Cham WT, Tang SP, et al. Brief report: first identification of intrafamilial recurrence of Blau syndrome due to gonosomal NOD2 mosaicism. Arthritis Rheumatol. 2016; 68(4): 1039–1044.
78. Mensa-Vilaro A, Teresa-Bosque M, Magri G, et al. Late onset cryopyrin-associated periodic syndrome due to myeloid-restricted somatic NLRP3 mosaicism. Arthritis Rheumatol. 2016; 68(12): 3035–3041.
79. Zhou Q, Aksentijevich I, Wood GM, et al. Brief report: cryopyrin-associated periodic syndrome caused by a myeloid-restricted somatic NLRP3 mutation. Arthritis Rheumatol. 2015; 67(9): 2482–2486.
80. Rowczenio D, Omoyinmi E, Trojer H, et al. First case of somatic mosaicism in TRAPS caused by a novel 24 nucleotides deletion in the TNFRSF1A gene. Pediatr Rheumatol Online J. 2015; 13(Suppl 1): O60.
81. Rowczenio DM, Gomes SM, Arostegui JI, et al. Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism—UK Single Center Experience. Front Immunol. 2017; 8: 1410.
82. Kontzias A, Zarabi S, Calabrese C, et al. Late onset tumour necrosis factor receptor (TNFR)–associated periodic syndrome (TRAPS) caused by somatic tnfrsf1 mosaicism. Ann Rheum Dis. 2018; 77: 1670-1671.
83. Jha S, Brickey WJ, Ting JP. Inflammasomes in Myeloid Cells: Warriors Within. Microbiol Spectr. 2017; 5(1): 10.
84. Shinar Y, Tohami T, Livneh A, et al. Acquired familial Mediterranean fever associated with a somatic MEFV mutation in a patient with JAK2 associated post-poly- cythemia myelofibrosis. Orphanet J Rare Dis. 2015; 10: 86.
85. Shinar Y, Cohen R, Marcu V, et al. Severe prognosis of late onset CAPS associated with age-related clonal hematopoiesis. Présentation de poster au 10ème congrès de l'ISSAID. Avril 2019.
86. Valent P, Kern W, Hoermann G, et al. Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. Int J Mol Sci. 2019; 20: 789.
87. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015; 126(1): 9-16.
88. Koning HD. Schnitzler’s syndrome: lessons from 281 cases. Clin Transl Allergy. 2014; 4(1): 41.
89. Rowczenio DM, Pathak S, Arostegui JI. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. Blood. 2018; 131(9): 974-981.
90. Simon A, Asli B, Braun-Falco M, et al. Schnitzler's syndrome: diagnosis, treatment, and follow‐up. Allergy. 2013; 68(5): 562– 568.
91. Terré A, Talbot A, Louvrier C, et al. Monoclonal gammopathy, arthralgias, and recurrent fever syndrome: a new autoinflammatory syndrome? J Rheumatol. 2019; 46(5).
92. Magadur-Joly G, Billaud E, Barrier JH, et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis. 1995; 54: 587-590.
93. Kurasawa M, Kotani K, Kurasawa G, et al. Adult-onset Still's disease in a patient over 80 years old successfully treated with low-dose methotrexate therapy. Age Ageing. 2007; 36(1): 104–106.
94. Wouters JM, van Rijswijk MH, van de Putte L, et al. Adult onset Still's disease in the elderly: a report of two cases. J Rheumatol. ; 12(4): 791-3.
95. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992; 19(3): 424-430.
96. Lebrun D, MSDMea. Validation of the Fautrel classification criteria for adult-onset Still’s disease. Semin Arthritis Rheum. 2018; 47(4): 578-585.
97. Rigante D, Vitale A, Natale MF, et al. A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. J Clin Rheumatol. 2017; 36(2): 463–8.
98. Vitale A, Orlando I, Lopalco G, et al. Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome. Clin Exp Rheumatol. 2016; 34: 77-81.
99. Cattalini M, Soliani M, Rigante D, et al. Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease. Mediators Inflamm. 2015; 2015: 570418.
100. De Pauli S, Lega S, Pastore S, et al. Neither hereditary periodic fever nor periodic fever, aphthae, pharingitis, adenitis: Undifferentiated periodic fever in a tertiary pediatric center. World J Clin Pediatr. 2018; 7(1): 49-55.
101. Toplak N, Frenkel J, Ozen S, et al. An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis. 2012; 71(7): 1177-82.
102. Georgin-Lavialle S, Stankovic K, Bachmeyer C, et al. Les maladies autoinflammatoires inclassées existent-t- elles? A propos de 56 cas adultes (abstract). Rev Med Interne. 2016; 37(1): A68.
103. Piram M, Frenkel J, Gattorno M, et al. A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Ann Rheum Dis. 2011; 70(2): 309–314.
104. Piram M, Koné-Paut I, Lachmann HJ, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2014; 73(12): 2168–2173.
105. Vitale A, Rigante D, Lucherini OM, et al. Biological Treatments: New Weapons in the Management of Monogenic Autoinflammatory Disorders. Mediators Inflamm. 2013; 2013: 939847.
106. Georgin-Lavialle S, Rodrigues F, Hentgen V, et al. Panorama des maladies auto-inflammatoires. Rev Med Interne. 2018; 39: 214–232.
107. Sack, Jr GH. Serum amyloid A – a review. Mol Med. 2018; 24: 46.
108. Berkun Y, Padeh S, Reichman B, et al. A single testing of serum amyloid A levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin. Arthritis Rheum. Semin Arthritis Rheum. 2007; 37(3): 182–188.
109. Stankovic Stojanovica K, Hentgen V, Fellahi S, et al. Concordance between CRP and SAA in familial Mediterranean fever during attack-free period: A study of 218 patients. Clin Biochem. 2017; 50(4-5): 206-209.
110. Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol. 2011; 7: 105–112.
111. Shinar Y, Obici L, Aksentijevich I, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis. 2012;71(10):1599–1605. Ann Rheum Dis. 2012; 71(10): 1599–1605.
112. Federici S, Vanoni F, Ben-Chetrit E, et al. An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor–associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. J Rheumatol. 2019; 46(5).
113. Yao Q, Lacbawan F, Li J. Adult autoinflammatory disease frequency and our diagnostic experience in an adult autoinflammatory clinic. Semin Arthritis Rheum. 2016; 46(5): 633-637.
114. Omoyinmi E, Standing A, Keylock A, et al. Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis. PLoS ONE. 2017; 12(7): e0181874.
115. Sarrabay G, Tachon G, Mechin D, et al. NGS for the diagnosis of autoinflammatory diseases: the experience of Montpellier. Pediatr Rheumatol. 2015; 13(1): O17.
116. Rowczenio DM, Lachmann HJ. How to prescribe a genetic test for the diagnosis of autoinflammatory diseases? Presse Med. 2019; 48(1): e49-e59.
117. Rusmini M, Federici S, Caroli F, et al. Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases. Ann Rheum Dis. 2016; 75: 1550-1557.
118. Ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015; 74: 1636-1644.
119. Ter Haar N, Lachamnn HJ, Özen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013; 72(5): 678-85.
120. Kuemmerle-Deschner J, Schock A, Hansmann S, et al. THU0624 Colchicine: an effective treatment option for unclassified autoinflammatory diseases in children. Ann Rheum Dis. 2018; 77: 509.
121. Hausmann JS, Guben B, Anderson E, et al. Predicting Colchicine Response in Patients with Undefined Autoinflammatory Diseases [abstract]. 2017; 69(suppl 4).
122. Liantinioti G, Argyris AA, Protogerou AD, et al. The Role of Colchicine in the Treatment of Autoinflammatory Diseases. Curr Pharm Des. 2018; 24(6): 690-694.
123. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016; 75: 644-651..
124. Hoffman HM. Therapy of autoinflammatory syndromes. J Allergy Clin Immunol. 2009; 124(6): 1129–1140..
125. Erbis G, Sergiichuk T, Bensele SM, et al. Determinants of health-related quality of life in children and adults with autoinflammatory diseases. Pediatr Rheumatol. 2015; 13(Suppl 1): P174.
126. Erbis G, Schmidt K, Hansmann S, et al. Living with autoinflammatory diseases: identifying unmet needs of children, adolescents and adults. Pediatr Rheumatol Online J. 2018; 16(1): 81.
127. Lepore L, Paloni G, Caorsi R, et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr. 2010; 157(2): 310–315.
128. Duruoz MT, Unal C, Bingul DK, et al. Fatigue in familial Mediterranean fever and its relations with other clinical parameters. Rheumatol Int. 2018; 38(1): 75-81.
129. Lane T, Loeffler JM, Rowczenio DM, et al. Brief Report: AA Amyloidosis Complicating the Hereditary Periodic Fever Syndromes. Arthritis Rheum. 2013; 65: 1116-1121.
130. Obici L, Merline G. Amyloidosis in autoinflammatory syndromes. Autoimmun Rev. 2012; 12(1): 14-17.
131. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007; 356(23): 2361-71.
132. Ayar Y, Ersoy A, Oksuz MF, et al. Clinical outcomes and survival in AA amyloidosis patients. Rev Bras Reumatol Engl Ed. 2017; 57(6): 535-544.
133. Ahbap E, Kara E, Sahutoglu T, et al. Outcome of 121 patients with renal amyloid a amyloidosis. 2014; 19(7): 644–649.